Earli is a biotechnology company focused on making cancer that is detected early, localizable and therefore treatable, via its novel “Synthetic Biopsies.”

Earli’s mission is to make cancer a benign experience, by catching and curing it early.

Earli was founded in 2018 by Cyriac Roeding, and Dr. David Suhy, with late Dr. Sam Gambhir. The company is headquartered in South San Francisco, California.

 

Earli is creating a new platform technology called a “Synthetic Biopsy,” which uses genetic constructs to force cancer to produce biomarkers not normally expressed in the human body.

 

Earli uses biology to produce a series of cancer-activated synthetic biomarkers designed to detect the exact location of the malignancy within a specific tissue, so it can be treated via precision surgery or targeted radiation, or new immuno-oncology techniques.

 

Earli is backed by Khosla Ventures, Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital, Marc Benioff, Menlo Ventures andd others. The company raised $40M in Series A round on Jan 12, 2021. This brings Earli's total funding to approx. $60M to date.

 

 

  • Year founded: 2018
  • Funding Info: Approx. $60M over 2 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: South San Francisco
  • State: California
  • Country: United States
Related businesses